Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?

Objectives: The aim of this study was to evaluate the efficacy and safety of sofosbuvir/ledipasvir ± ribavirin in Malagasy patients with hepatitis C virus genotypes 1 and 2, in real conditions. Patients and methods: This was a retrospective monocentric clinical study, carried out over a period of 3...

Full description

Bibliographic Details
Main Authors: Chantelli Iamblaudiot Razafindrazoto, Anjaramalala Sitraka Rasolonjatovo, Tovo Harimanana Rabenjanahary, Nitah Harivony Randriamifidy, Andry Lalaina Rinà Rakotozafindrabe, Soloniaina Hélio Razafimahefa, Rado Manitrala Ramanampamonjy
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:International Journal of Infectious Diseases
Subjects:
Viral hepatitis C
Sofosbuvir
Ledipasvir
Ribavirin
Madagascar
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221003738

Similar Items

Similar Items